Financial Data and Key Metrics Changes - Revenue for the fourth quarter was $700,000, with research and development expenses increasing to $25.3 million from $18.4 million year-over-year, primarily due to advancements in internal programs [26][27] - Selling, general, and administrative expenses were $8.6 million, slightly down from $8.8 million in the prior year [26] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $144.3 million, down from $152.5 million as of September 30, 2025 [27] Business Line Data and Key Metrics Changes - The company is advancing its lead program, ABS-201, for androgenetic alopecia (AGA) and endometriosis, with ongoing clinical trials showing favorable safety data [7][19] - ABS-201 is designed to provide durable hair regrowth with a convenient dosing regimen, potentially requiring only two to three administrations over a six-month period [10][11] Market Data and Key Metrics Changes - The total addressable market for ABS-201 in the U.S. for AGA is estimated at approximately 15-18 million consumers, with potential annual treatable patient volume ranging from 5-9 million [22][23] - The market for endometriosis is also significant, with an estimated 10% of women of reproductive age affected globally, and no FDA-approved disease-modifying therapy currently available [12][14] Company Strategy and Development Direction - The company aims to target underexplored areas in large markets with significant unmet needs and low competition, focusing resources on ABS-201 while seeking partnerships for other programs [13][14] - The strategy includes leveraging the generative AI platform, Origin-1, for efficient drug design and development, which has shown to reduce time and costs compared to industry standards [14][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical momentum and the ability to reach proof of concept for both AGA and endometriosis, with key data readouts expected in 2026 and 2027 [29] - The company is well-positioned financially to support ongoing operations and clinical trials into the first half of 2028 [27][28] Other Important Information - The company has expanded its advisory networks for both AGA and endometriosis, enhancing trial design and endpoint selection [9] - The engagement with patients and advocacy groups has reinforced the need for better treatment options in endometriosis, which has been underserved for decades [11][12] Q&A Session Summary Question: What should investors look for in terms of ABS-201's target product profile? - Management aims for ABS-201 to achieve durable treatment and efficacy at or above minoxidil levels, with a target of 35-40 hairs per square centimeter [31][34] Question: Can you elaborate on the safety profile observed in the SAD portion of the trial? - Early data shows no evidence of on-target or off-target safety signals, which is encouraging [39][40] Question: How do you envision ABS-201 being used in relation to other agents like clascoterone? - Management sees ABS-201 as a synergistic option that could provide durable hair regrowth with fewer doses compared to daily treatments [68][70] Question: What are the expected challenges in developing a drug for endometriosis? - Pain studies require careful consideration in site selection and protocol design to mitigate placebo effects [84] Question: How should resource allocation be viewed between AGA and endometriosis? - Both programs are seen as significant opportunities, with a streamlined development path allowing for efficient resource allocation [85]

We’re excited to be working with @JNJInnovation to accelerate the path to new medicines. This collaboration brings @IsomorphicLabs' AI drug design engine together with J&J’s world-class drug development capabilities to tackle historically difficult to drug disease targets. A big step forward for digital biology! 🧬Isomorphic Labs (@IsomorphicLabs):@IsomorphicLabs today announced a cross-modality and multi-target research collaboration with @JNJInnovation. The partnership brings together Isomorphic’s AI-first ...

AI在药物设计中的应用 - Isomorphic Labs 旨在创建一个 AI 药物设计引擎，能够针对任何疾病和蛋白质靶点，设计出调节蛋白质和细胞功能的分子，从而改善患者的病情 [1] - 行业普遍认为，五年内，不使用 AI 进行药物设计就像在科学研究中不使用数学一样 [1][43] - AlphaFold 3 可以在几秒钟内预测分子结构，而传统的 X 射线晶体学方法可能需要数月甚至数年 [3] - AI 模型通过分析包含数十万个 3D 结构的蛋白质数据库（Protein Data Bank, PDB），学习并泛化到新的蛋白质和分子 [2] - AI 可以通过生成模型和搜索方法，在 10^60 数量级的巨大分子设计空间中进行智能探索，找到合适的药物分子 [2] 药物研发的挑战与未来 - 解决复杂疾病的难点在于对疾病驱动因素的理解不足，以及癌症等疾病的持续进化 [1][2] - 药物设计不仅要考虑分子与靶蛋白的结合，还要考虑结合强度、对其他蛋白质的潜在副作用、稳定性、溶解性等多种相互制约的因素 [6][7] - 临床试验失败率高达 90%，主要原因是动物模型不能很好地复制人类生理 [27][28] - AI 可以通过预测分子与其他蛋白质的相互作用，在药物设计早期发现潜在的毒性和副作用 [31][32] - 药物研发行业有很高的失败率，平均 20 个药物化学家只有 1 个能成功将药物推向市场 [39] - 预计未来五年内，将会有 AI 设计的药物获得批准上市，AI 将在药物研发的各个阶段发挥更大的作用 [41][42]